NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 106.4% and is now trading at $24.83. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.16. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $4.92 million. View Cytokinetics' earnings history.

7 Wall Street analysts have issued 12-month price targets for Cytokinetics' stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Cytokinetics' stock price to reach $26.43 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View analysts' price targets for Cytokinetics.

News articles about CYTK stock have trended negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytokinetics earned a news impact score of -2.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days. View the latest news about Cytokinetics.

Cytokinetics saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 7,720,000 shares, a decrease of 6.3% from the June 15th total of 8,240,000 shares. Based on an average daily trading volume, of 867,200 shares, the short-interest ratio is currently 8.9 days. Approximately 14.2% of the company's shares are sold short. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include PPD (SDGR), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Myokardia (MYOK), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), Biohaven Pharmaceutical (BHVN), Global Blood Therapeutics (GBT), Evotec (EVTCY) and Amicus Therapeutics (FOLD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $24.83.

Cytokinetics has a market capitalization of $1.48 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]